Skip to main content
NCBI home page
Applied and Environmental Microbiology logoLink to Applied and Environmental Microbiology
. 1990 Jan;56(1):264–268. doi: 10.1128/aem.56.1.264-268.1990

Model for inactivation and disposal of infectious human immunodeficiency virus and radioactive waste in a BL3 facility.

M C Stinson 1, M S Galanek 1, A M Ducatman 1, F X Masse 1, D R Kuritzkes 1
PMCID: PMC183304  PMID: 2310182

Abstract

A method is described for autoclaving low levels of solid infectious, radioactive waste. The method permits steam penetration to inactivate biologic waste, while any volatile radioactive compounds generated during the autoclave process are absorbed. Inactivation of radiolabeled infectious waste has been problematic because the usual sterilization techniques result in unacceptable radiation handling practices. If autoclaved under the usual conditions, there exists a high probability of volatilization or release of radioisotopes from the waste. This results in the radioactive contamination of the autoclave and the laboratory area where steam is released from the autoclave. Our results provide a practical method to inactivate and dispose of infectious radioactive waste. For our research, Bacillus pumilus spore strips and vaccinia virus were used as more heat-resistant surrogates of the human immunodeficiency virus (HIV). These surrogates were used because HIV is difficult to grow under most conditions and is less heat tolerant than the surrogates. In addition, B. pumilus has defined cell death values, whereas such values have not been established for HIV. Both B. pumilus and vaccinia virus are less hazardous to work with. The autoclave method is time efficient and can be performed by laboratory personnel with minimal handling of the waste. Furthermore, waste site handlers are able to visually inspect the solid waste containers and ascertain that inactivation procedures have been implemented.

Full text

PDF
264

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Atkinson W. Replacing the 'soft' touch with the safe touch. Occup Health Saf. 1989 Jan;58(1):20-3, 34. [PubMed] [Google Scholar]
  2. Barré-Sinoussi F., Chermann J. C., Rey F., Nugeyre M. T., Chamaret S., Gruest J., Dauguet C., Axler-Blin C., Vézinet-Brun F., Rouzioux C. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science. 1983 May 20;220(4599):868–871. doi: 10.1126/science.6189183. [DOI] [PubMed] [Google Scholar]
  3. Gallo R. C., Salahuddin S. Z., Popovic M., Shearer G. M., Kaplan M., Haynes B. F., Palker T. J., Redfield R., Oleske J., Safai B. Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS. Science. 1984 May 4;224(4648):500–503. doi: 10.1126/science.6200936. [DOI] [PubMed] [Google Scholar]
  4. Harada S., Yoshiyama H., Yamamoto N. Effect of heat and fresh human serum on the infectivity of human T-cell lymphotropic virus type III evaluated with new bioassay systems. J Clin Microbiol. 1985 Dec;22(6):908–911. doi: 10.1128/jcm.22.6.908-911.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Heyward W. L., Curran J. W. The epidemiology of AIDS in the U.S. Sci Am. 1988 Oct;259(4):72–81. doi: 10.1038/scientificamerican1088-72. [DOI] [PubMed] [Google Scholar]
  6. Ho D. D., Schooley R. T., Rota T. R., Kaplan J. C., Flynn T., Salahuddin S. Z., Gonda M. A., Hirsch M. S. HTLV-III in the semen and blood of a healthy homosexual man. Science. 1984 Oct 26;226(4673):451–453. doi: 10.1126/science.6208608. [DOI] [PubMed] [Google Scholar]
  7. Levy J. A., Mitra G. A., Wong M. F., Mozen M. M. Inactivation by wet and dry heat of AIDS-associated retroviruses during factor VIII purification from plasma. Lancet. 1985 Jun 22;1(8443):1456–1457. doi: 10.1016/s0140-6736(85)91888-4. [DOI] [PubMed] [Google Scholar]
  8. Martin L. S., McDougal J. S., Loskoski S. L. Disinfection and inactivation of the human T lymphotropic virus type III/Lymphadenopathy-associated virus. J Infect Dis. 1985 Aug;152(2):400–403. doi: 10.1093/infdis/152.2.400. [DOI] [PubMed] [Google Scholar]
  9. Resnick L., Veren K., Salahuddin S. Z., Tondreau S., Markham P. D. Stability and inactivation of HTLV-III/LAV under clinical and laboratory environments. JAMA. 1986 Apr 11;255(14):1887–1891. [PubMed] [Google Scholar]
  10. Weiss S. H., Goedert J. J., Gartner S., Popovic M., Waters D., Markham P., di Marzo Veronese F., Gail M. H., Barkley W. E., Gibbons J. Risk of human immunodeficiency virus (HIV-1) infection among laboratory workers. Science. 1988 Jan 1;239(4835):68–71. doi: 10.1126/science.3336776. [DOI] [PubMed] [Google Scholar]

Articles from Applied and Environmental Microbiology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES